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For the prevention of the immunological chronic rejection， HLA-DRBl allele matching， enough 
immunosuppression in the induction phase and pathological diagnosis by non-episode and protocol 
biopsy are the effective methods. 
For the prevention of the non-immunological chronic rejection， treatments for hypertension， 
hyperlipidemia and hyper印trationare the effective treatments. 
(Acta Urol. Jpn. 48: 683-686， 2002) 




























1 )組織適合性:Class 1遺伝子の中の， DRBI 
alleleのみの一致で良好な長期生着が得られることが




程度で十分であることが証明されている (Fig.2) 2) 
一ーー DRB1alele∞mpalible (N=40) 




Fig. 1. DRBl allele compatibility and graft survival 
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Fig. 2. Amino acid residues mismatch of the DRB 1 first domain on 
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183 28 61 91 
Tlme slnce transplantatlon (d置ys)
Biopsy date: years after transplantation， n.p: normal 
findings， CR: chronic rejection. Kyo M， Hatori M， 
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Fig. 3. Proportion of patients free from biopsy-
co凶 rmed acute rejection (Kaplan-
Meier analysis) (Margreiter R， etal.: 
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Fig. 4. Total cholesterol level， triglyceride level 
and the effect of the administration of 
HMG-CoA inhibitor (市丸直嗣，高原史









































































24 hour urine protein level， renal function and the effect of 
the administration of ACE inhibitor (Oka K， Takahara S， 
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Fig. 6. A: Effect of the administration of hepa-
tocyte growth factor on rat model to 
prevent chronic rejection (uri町 pro-
tein). B: Effect of the administration 
of hepatocyte growth factor on rat mod-
el to prevent chronic rejection (graft sur-
vival rate) (共に AzumaH， Takahara 
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